A Follow-up Study to Assess Resistance to ABT-072 in HCV-infected Subjects Administered ABT-072 in Prior ABT-072 Studies

Study Identifier
M10-605
CT.gov Identifier
NCT00872196
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Hepatitis
    • Study Drug
  • ABT-072
    • Phase
    Phase 2
    Sex
    Female & Male
    Age
    18 - 65 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    \- Main Selection Criteria: A subject that has received either ABT-072 or placebo in a prior study involving ABT-072.
    Exclusion Criteria:
    \- The investigator considers the subject unsuitable for the study for any reasons inclusive of, but not limited to, failure to comply with study procedures in a prior ABT-072 clinical study.

    Protocol Summary

    This is a follow-up study with no treatment and only samples being collected.

    Study Locations

    Location
    Status
    Location
    Site Reference ID/Investigator# 18222
    Los Angeles, California, United States, 90036
    Status
    Not applicable